2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Great Hall AD
Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, Clinical Research, Clinical Trials, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

61 Rapid and deep molecular MRD clearance with venetoclax plus “7+3” in newly diagnosed NPM1-mutated AML: Subgroup analysis of a phase 1b trial

Josette Kamel, MD, Briana Friedman2, Mendel Goldfinger, MD3, Chenxin Zhang, MS4, Kira Gritsman, MD, PhD5, Aditi Shastri, MD6, Noah Kornblum, MD7, Lauren C. Shapiro, MD8, R. Alejandro Sica, MD9, David Levitz, MD10, Ridhi Gupta, MD11, Shyamala Navada, MD12, Vincent Rella, MD13, Jhannine Verceles14, Davina Hoban15, Aradhika Dhawan16, Annemarie Munoz17, Lamisha Shah18, Amit Verma, MD19, Dennis Cooper, MD20, Mimi Kim, Sc.D21, Marina Konopleva, MD, PhD22, Eric Feldman, MD23, Ioannis Mantzaris, MD, MS24
1 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
2 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
3 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
4 Albert Einstein College of Medicine, The Bronx, New York, United States
5 Albert Einstein College of Medicine, The Bronx, New York, United States
6 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
7 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
8 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
9 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
10 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
11 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
12 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
13 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
14 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
15 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
16 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
17 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
18 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
19 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
20 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
21 Albert Einstein College of Medicine, The Bronx, New York, United States
22 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
23 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States
24 Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, New York, United States

Background: NPM1 mutations (NPM1m) occur in approximately 30% of de novo acute myeloid leukemia (AML). Although intensive chemotherapy (IC) induces high remission rates, persistent measurable residual disease (MRD) remains a major driver of relapse. Given the robust activity of venetoclax (Ven) plus hypomethylating agents in older or unfit patients, particularly those with NPM1m AML, combining BCL-2 inhibition with IC represents a rational strategy to enhance antileukemic activity in younger, fit patients. Preliminary safety and efficacy data from an ongoing phase 1b trial of Ven plus "7+3" in newly diagnosed AML (NCT05342584) have been previously reported. Here, we present outcomes in the NPM1m molecular subgroup.

Methods: We performed a subgroup analysis of adult patients with newly diagnosed NPM1m AML enrolled in this study. Patients were stratified by age (≤60 vs >60 years) and received Ven in combination with standard "7+3" induction (Ven 400 mg for 8, 11, or 14 days), followed by age-adjusted intermediate-dose cytarabine (aaIDAC) with Ven (200 mg for 5–7 days) for consolidation. Adverse events (AEs) were graded according to CTCAE v5.0. Efficacy endpoints included composite complete remission (CRc; CR+CRh+CRi), MRD-negative CRc by MFC and NPM1 RT-qPCR at the end of induction (EOI) and at any time, and allogeneic hematopoietic stem cell transplantation (HSCT) in first remission (CR1); exact binomial 95% CIs were calculated. MRD was assessed centrally by multiparameter flow cytometry (MFC; limit of detection <0.02%) at Hematologics and NPM1 RT-qPCR, in a subset of patients (ARUP; LOD 10?5). Time to MRD-negative CR, duration of response (DoR), EFS, and OS were estimated by Kaplan-Meier.

Results: As of July 10, 2026, 23 patients with NPM1m AML were enrolled and evaluable. Median age was 57 years (range 25–73), 56.5% were male, and 52.2% non-White. By ELN 2022 classification, 15 patients had favorable-, 6 intermediate-, and 1 adverse-risk disease; FLT3-ITD co-occurred in 26% (6/23).

There were no treatment-related deaths. The most common treatment-emergent adverse events were febrile neutropenia (100%), bacteremia/sepsis (26%), lung infection (22%), and neutropenic enterocolitis (13%). Median time to ANC ≥1.0×10?/L and platelet ≥100×10?/L recovery was 27 days for both.

CR was achieved in all patients (100%; 95% CI, 85.2–100.0). Complete molecular remission by NPM1 RT-qPCR was achieved in 70% (14/20; 95% CI, 45.7–88.1) at the end of induction and in all evaluable patients (22/22) during therapy, with a median time to PCR negativity of 1.05 (1.02–1.97) months. MFC MRD-negative CR was achieved in all patients at end of induction.

Twelve patients (52.2%) completed protocol therapy with 3–4 cycles of IDAC+Ven, of whom 9 received off-protocol HMA-based maintenance at the treating physician's discretion. Eight patients (36.4%; 95% CI, 17.2–59.3) proceeded to HSCT in CR1 because of ELN 2022 risk, co-mutations, or older age, including 4 with FLT3-ITD AML who were taken off protocol therapy to receive FLT3 inhibitor–based consolidation. One patient discontinued because of geographic relocation.

At a median follow-up of 29.7 months, median duration of response, EFS, and OS were not reached. Estimated 1- and 2-year EFS was 81.3% (95% CI, 66.4–99.7) and 64.7% (95% CI, 46.4–90.2), respectively; corresponding OS was 100% and 94.4% (95% CI, 84.4–100.0).

Conclusions: Venetoclax combined with standard "7+3" chemotherapy demonstrated manageable toxicity and induced high rates of deep molecular remission in newly diagnosed NPM1-mutated AML. MFC MRD-negative CR was achieved in all responding patients at the end of induction, and complete molecular remission was achieved rapidly, with all evaluable patients becoming PCR-negative by the end of consolidation. Responses were durable, with encouraging EFS and OS. With the emergence of menin inhibitors as a highly promising targeted therapy for NPM1-mutated AML, future studies should evaluate their integration with venetoclax-based intensive chemotherapy in the frontline setting.

 

Josette Kamel, MD: No relevant conflicts of interest to declare.